Table 1 Patient baseline demographic and clinical characteristics in cohort 1 (Apatinib-based vs. Chemotherapy-based)
| Â | Initial cohort | Â | Propensity-score-matched cohort | Â | |||||
|---|---|---|---|---|---|---|---|---|---|
|  | Apatinib Based (n = 56) | Chemotherapy Based (n = 107) | P |  | Apatinib Based (n = 30) | Chemotherapy Based (n = 30) | P | ||
Age, years | Â | Â | Â | Â | Â | Â | Â | ||
 < 50 | 26 (46.4) | 54 (50.5) | 0.745 |  | 16 (53.3) | 18 (60.0) | 0.794 | ||
 ≥ 50 | 30 (53.6) | 53 (49.5) |  |  | 14 (46.7) | 12 (40.0) |  | ||
ECOG PS at start | Â | Â | Â | Â | Â | Â | Â | ||
 0 | 7 (12.5) | 13 (12.1) | 1.000 |  | 3 (10.0) | 2 (6.7) | 1.000 | ||
 ≥ 1 | 49 (87.5) | 94 (87.9) |  |  | 27 (90.0) | 28 (93.3) |  | ||
Menopausal status at diagnosis | Â | Â | Â | Â | Â | Â | Â | ||
 Premenopausal | 41 (73.2) | 80 (74.8) | 0.979 |  | 7 (23.3) | 6 (20.0) | 1.000 | ||
 Postmenopausal | 15 (26.8) | 27 (25.2) |  |  | 23 (76.7) | 24 (80.0) |  | ||
Surgery on primary tumor | Â | Â | Â | Â | Â | Â | Â | ||
 Yes | 37 (66.1) | 83 (77.6) | 0.163 |  | 21 (70.0) | 26 (86.7) | 0.210 | ||
 No | 19 (33.9) | 24 (22.4) |  |  | 9 (30.0) | 4 (13.3) |  | ||
TNBC at the initial onset | Â | Â | Â | Â | Â | Â | Â | ||
 Yes | 48 (85.7) | 76 (71.0) | 0.058 |  | 26 (86.7) | 23 (76.7) | 0.505 | ||
 No | 8 (14.3) | 31 (29.0) |  |  | 4 (13.3) | 7 (23.3) |  | ||
Ki67 ≥ 30% | 48 (85.7) | 94 (87.9) | 0.888 |  | 27 (90.0) | 28 (93.3) | 1.000 | ||
Metastatic sites | Â | Â | Â | Â | Â | Â | Â | ||
 Visceral | 29 (51.8) | 59 (55.1) | 0.808 |  | 15 (50.0) | 17 (56.7) | 0.796 | ||
 Non-visceral | 27 (48.2) | 48 (44.9) |  |  | 15 (50.0) | 13 (43.3) |  | ||
Metastatic sites > 3 | 16 (28.6) | 54 (50.5) | 0.012 |  | 9 (30.0) | 12 (40.0) | 0.588 | ||
Location of metastases | Â | Â | Â | Â | Â | Â | Â | ||
 Brain | 2 (3.6) | 7 (6.5) | 0.669 |  | 1 (3.3) | 0 (0.0) | 1.000 | ||
 Bone | 19 (33.9) | 49 (45.8) | 0.196 |  | 9 (30.0) | 9 (30.0) | 1.000 | ||
 Liver | 8 (14.3) | 23 (21.5) | 0.366 |  | 4 (13.3) | 5 (16.7) | 1.000 | ||
 Lung | 22 (39.3) | 45 (42.1) | 0.862 |  | 11 (36.7) | 13 (43.3) | 0.792 | ||
 Lymph node | 40 (71.4) | 76 (71.0) | 1.000 |  | 21 (70.0) | 22 (73.3) | 1.000 | ||
 Adrenal glands | 1 (1.8) | 3 (2.8) | 1.000 |  | 1 (3.3) | 1 (3.3) | 1.000 | ||
 Chest wall | 5 (8.9) | 15 (14.0) | 0.491 |  | 3 (10.0) | 3 (10.0) | 1.000 | ||
(Neo-) Adjuvant therapies | Â | Â | Â | Â | Â | Â | Â | ||
 Paclitaxel/Docetaxel | 34 (60.7) | 73 (68.2) | 0.432 |  | 19 (63.3) | 20 (66.7) | 1.000 | ||
 Anthracyclines | 33 (58.9) | 81 (75.7) | 0.042 |  | 19 (63.3) | 20 (66.7) | 1.000 | ||
 Paclitaxel/Docetaxel and Anthracyclines | 31 (55.4) | 71 (66.4) | 0.227 |  | 18 (60.0) | 20 (66.7) | 0.789 | ||
 Platinum (Cis/Carbo) | 4 (7.1) | 4 (3.7) | 0.566 |  | 2 (6.7) | 2 (6.7) | 1.000 | ||
 Capecitabine | 4 (7.1) | 4 (3.7) | 0.566 |  | 2 (6.7) | 2 (6.7) | 1.000 | ||
Treatment | Â | Â | Â | Â | Â | Â | Â | ||
 anti-PD-1/L1 antibody | 19 (33.9) | 4 (3.7) | < 0.001 |  | 5 (16.7) | 3 (10.0) | 0.704 | ||
 Nab-paclitaxel | 18 (32.1) | 14 (13.1) | 0.007 |  | 6 (20.0) | 5 (16.7) | 1.000 | ||
 Eribulin | 12 (21.4) | 13 (12.1) | 0.183 |  | 6 (20.0) | 3 (10.0) | 0.470 | ||
 Paclitaxel/Docetaxel | 2 (3.6) | 34 (31.8) | < 0.001 |  | 2 (6.7) | 3 (10.0) | 1.000 | ||
 Other chemotherapy (Platinum, Capecitabine, Gemcitabine, NVB, etc.) | 27 (48.2) | 87 (81.3) | < 0.001 |  | 21 (70.0) | 24 (80.0) | 0.551 | ||
Lines of therapy |  |  |  |  |  |  |  | ||
 1st Line | 16 (28.6) | 59 (55.1) | 0.002 |  | 8 (26.7) | 8 (26.7) | 1.000 | ||
 2nd+ Line | 40 (71.4) | 48 (44.9) |  |  | 22 (73.3) | 22 (73.3) |  | ||